# A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases

> **NCT06088056** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 17 (estimated)

## Conditions studied

- Breast Cancer
- Brain Metastases
- Radiotherapy

## Interventions

- **DRUG:** Combination use of SRT with T-DXd

## Key facts

- **NCT ID:** NCT06088056
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11
- **Primary completion:** 2024-06
- **Final completion:** 2026-07
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06088056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06088056, "A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06088056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*